AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1.-11. (Canceled).
- 12. (Currently Amended) A method for providing kidney protection from a kidney dysfunction caused by lithium which comprises administering to an individual in need thereof 2–5 mg of acetyl L-carnitine and 2–5 mg of propionyl L-carnitine/kg body weight/day or an equimolar amount of a pharmacologically acceptable salt thereof in which the weight-ratio of acetyl L-carnitine to propionyl L-carnitine is 1:1.
- 13. (Currently Amended) A method for providing protection from a kidney dysfunction caused by lithium which comprises administering to an individual in need thereof a combination composition of acetyl L-carnitine and propionyl L-carnitine or pharmacologically acceptable salt thereof, in which the weight-ratio of acetyl L-carnitine to propionyl L-carnitine is [[from]]-1:1-to 1:10.
- 14. (Currently Amended) A method for providing protection from nephropathy caused by lithium which comprises administering to an individual in need thereof a combination composition of acetyl L-carnitine and propionyl L-carnitine or pharmacologically acceptable salt thereof, in which the weight-ratio of acetyl L-carnitine to propionyl L-carnitine is [[from]]-1:1-to 1:10.
 - 15.-16. (Canceled).
 - 17.-22. (Canceled).
 - 23.-24. (Canceled).
 - 25.-30. (Canceled).

CAVAZZA Appl. No. 10/667,482 October 30, 2008

- 31. (Currently Amended) A method for providing protection from a tubular necrosis caused by lithium which comprises administering to an individual a combination composition of acetyl L-carnitine and propionyl L-carnitine or pharmacologically acceptable salt thereof, in which the weight ratio of acetyl L-carnitine to propionyl L-carnitine is [[from]]-1:1-to-1:10.
- 32. (Currently Amended) A method for providing protection from a tubular necrosis caused by lithium which comprises administering 2–5 mg of acetyl L-carnitine and 2–5 mg of propionyl L-carnitine/kg body weight/day or an equimolar amount of a pharmacologically acceptable salt thereof in which the weight ratio of acetyl L-carnitine to propionyl L-carnitine is 1:1.
 - 33.-35. (Canceled).